Skip to content

Study · Case report or series · n = 1 · 2025

4 results

Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide.

Ahern S

Cureus8 Oct 2025Cited by 5 (Europe PMC)

PMID41210042 (opens in a new tab)PMCIDPMC12594042 (opens in a new tab)DOI10.7759/cureus.94126 (opens in a new tab)PepBankPUB-41210042
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

Semaglutide and tirzepatide are two commonly prescribed glucagon-like peptide-1 (GLP-1) and GLP-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonists used for the treatment of type 2 diabetes and chronic weight management. Allodynia and dysesthesia have been previously reported as effects of semaglutide. This case report adds to the literature on dysesthesia from semaglutide and presents a novel report in a patient taking tirzepatide. This adverse drug reaction occurs in both patients treated for type 2 diabetes and chronic weight management, appears to be dose dependent, and resolves with discontinuation of the drug and may resolve spontaneously after several weeks.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    A case report describes a novel case of dysesthesia in a patient taking tirzepatide.

    In plain wordsA case report describes nerve-related skin sensations (dysesthesia) in a person taking tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Not applicableDysesthesia or allodynia with tirzepatide
    Study

    n = 1

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This case report adds to the literature on dysesthesia from semaglutide and presents a novel report in a patient taking tirzepatide.
  2. 02HumanCase report or seriesSafety outcome

    A case report adds to the literature on dysesthesia associated with semaglutide.

    In plain wordsA case report adds to existing reports of nerve-related skin sensations (dysesthesia) linked to semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableDysesthesia or allodynia with semaglutide
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This case report adds to the literature on dysesthesia from semaglutide and presents a novel report in a patient taking tirzepatide.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 03HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In patients treated with semaglutide or tirzepatide, the reaction appears dose dependent and resolves with discontinuation of the drug or sometimes spontaneously after weeks.

    In plain wordsThe report says this reaction seems dose dependent and goes away after stopping the drug, or sometimes alone after weeks. It covers both drugs.

    Peptide
    Semaglutide
    Outcome
    Not applicableCourse of dysesthesia with GLP-1 based drugs (dose dependence, resolution)
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition

    Source sentences

    Summary
    This adverse drug reaction occurs in both patients treated for type 2 diabetes and chronic weight management, appears to be dose dependent, and resolves with discontinuation of the drug and may resolve spontaneously after several weeks.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 04HumanNot a test of Tirzepatide aloneCase report or seriesSafety outcome

    In patients treated with semaglutide or tirzepatide, the reaction appears dose dependent and resolves with discontinuation of the drug or sometimes spontaneously after weeks.

    In plain wordsThe report says this reaction seems dose dependent and goes away after stopping the drug, or sometimes alone after weeks. It covers both drugs.

    Peptide
    Tirzepatide
    Outcome
    Not applicableCourse of dysesthesia with GLP-1 based drugs (dose dependence, resolution)
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition

    Source sentences

    Summary
    This adverse drug reaction occurs in both patients treated for type 2 diabetes and chronic weight management, appears to be dose dependent, and resolves with discontinuation of the drug and may resolve spontaneously after several weeks.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.